CALCA and vascular insufficiency disorder: As of January 31, 2022, 172 reports involving CGRP-targeting drugs in VigiBase® belonged to the HLT “Peripheral Vasoconstriction, necrosis and vascular insufficiency”, including 99 reports under the PT “Raynaud’s phenomenon” and 58 reports under the PT “Peripheral coldness”.